Company intelligence / Profile preview

Dia-B

Evry-Courcouronnes, Île-de-France, France

Ownership: Private
Development stage: Other

Overview

Dia-B is a French biotechnology company dedicated to developing innovative therapies for the treatment of Type 2 Diabetes. A spin-off from INSERM and the Université Paris Cité, the company focuses on a novel therapeutic target, the Dia-B protein, which plays a crucial role in the preservation and regeneration of pancreatic beta-cell mass. By modulating this target, Dia-B aims to restore natural insulin production and improve glycemic control in patients. The company's lead program is currently in the pre-clinical stage, with the goal of providing a disease-modifying treatment that addresses the underlying causes of diabetes progression.

Therapeutic areas: Endocrinology
Modalities: Small moleculePeptides
Industry: Biotech

Partnerships

INSERM TransfertGenopole

Beyond the preview

Go deeper on Dia-B.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dia-B.

Explore the full profile